2/12
07:00 am
lgnd
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Low
Report
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
2/4
07:00 am
lgnd
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Low
Report
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
12/17
07:09 am
lgnd
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? [Yahoo! Finance]
Low
Report
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? [Yahoo! Finance]
12/10
09:42 am
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Royal Bank Of Canada from $234.00 to $235.00. They now have an "outperform" rating on the stock.
Low
Report
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Royal Bank Of Canada from $234.00 to $235.00. They now have an "outperform" rating on the stock.
12/10
08:08 am
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Stifel Nicolaus from $220.00 to $230.00. They now have a "buy" rating on the stock.
Low
Report
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Stifel Nicolaus from $220.00 to $230.00. They now have a "buy" rating on the stock.
12/9
04:25 pm
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
12/9
09:06 am
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $270.00 price target on the stock.
Low
Report
Ligand Pharmaceuticals (NASDAQ:LGND) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $270.00 price target on the stock.
12/9
07:00 am
lgnd
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Low
Report
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
11/26
02:11 pm
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
07:04 pm
lgnd
How Ligand Pharmaceuticals' Strong Q3 Results and Raised Guidance May Impact LGND Investors [Yahoo! Finance]
Medium
Report
How Ligand Pharmaceuticals' Strong Q3 Results and Raised Guidance May Impact LGND Investors [Yahoo! Finance]
11/19
08:17 am
lgnd
What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? [Yahoo! Finance]
Low
Report
What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? [Yahoo! Finance]
11/18
08:13 am
lgnd
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year [Yahoo! Finance]
Medium
Report
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year [Yahoo! Finance]
11/14
01:15 pm
lgnd
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.